XML 39 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Pfizer Collaboration and Share Purchase Agreement - Additional Information (Detail)
 3 Months Ended 9 Months Ended
May 05, 2016
USD ($)
Program
Product
$ / shares
shares
Sep. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Dec. 31, 2016
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Current portion of deferred revenue   $ 2,705,000   $ 2,705,000   $ 2,705,000
Pfizer Inc. [Member]            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Number of research programs, counterparty nomination | Program 5          
Research term, description       Under the Pfizer Collaboration Agreement, the parties agreed to collaborate during the four-year Research Term. During the Research Term, the Company is responsible to use its commercially reasonable efforts to advance up to five programs through to the selection of clinical candidates. At that stage, Pfizer may elect to license any of these Pfizer Programs exclusively and to have exclusive rights to undertake the clinical development of the resulting clinical candidates into products and the potential commercialization of any such products thereafter.    
Collaboration agreement, additional period after research program 2 years          
Revenue recognized   700,000 $ 400,000 $ 2,000,000 $ 800,000  
Deferred revenue   9,000,000   9,000,000    
Current portion of deferred revenue   $ 2,700,000   $ 2,700,000    
Maximum [Member] | Pfizer Inc. [Member]            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Expected earnings from milestone payments under research program $ 871,000,000          
Research, License and Option Agreement [Member] | Pfizer Inc. [Member]            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Upfront amount related to research and development services $ 10,000,000          
Number of potential products are successfully developed and commercialized | Product 5          
Collaboration agreement refundable $ 0          
Shares issued under equity agreement | shares 1,875,000          
Equity investment aggregate purchase price $ 30,000,000          
Purchase price per share | $ / shares $ 16.00          
Collaborative agreement research term 4 years          
Collaboration agreement termination period 90 days